GLPwatch
Xultophy for Obstructive sleep apnea
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for obstructive sleep apnea, and any use for this condition is off-label or investigational. Listed research suggests liraglutide may reduce weight and excessive daytime sleepiness in obese individuals with type 2 diabetes and obstructive sleep apnea, but these findings are from studies not designed to establish efficacy for this specific condition.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Obstructive sleep apnea |
| Approval status | Investigational / off-label |
| Research papers | 14 |
Xultophy is not FDA-approved for obstructive sleep apnea; the research below reflects investigational or off-label study only.
Research on liraglutide for obstructive sleep apnea (14)
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
- Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.
- Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).
- An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.
- Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
- Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.
- Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats.
- Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.
- Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results.
- Liraglutide innovations: a comprehensive review of patents (2014-2024).
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.